ABSTRACT: Effects and microbiota changes following oral lyophilized fecal microbiota transplantation capsules in canine with chronic enteropathy: A case report
Project description:This project centers on the analysis of the human gut microbiota by 3 complementary technologies- bottom-up metaproteomics, chemical isotope labeled LC-MS metabolomics, and proximity ligation metagenomics. Stool samples were collected from 7 rCDI patients participated in a clinical trial which compared 2 different treatments: lyophilized fecal microbiota transplantation (LFMT) or lyophilized sterile fecal filtrate (LSFF) at week 0 and 24 weeks after intervention. These samples were processed for genomes, proteins, and metabolites which inform evolving host-microbiota and microbiota-microbiota interaction over time. All patients were successfully treated. In conjunction, the composition of LSFF treatment relative to the unfiltered LFMT is also explored.
Project description:Faecal Microbiota Transplantation for Pelvic Radiation-Induced Enteropathy
| PRJNA1438805 | ENA
Project description:Case Report: Microbial changes and clinical findings following long-term fecal microbiota transplantation in a severe ulcerative colitis patient
Project description:We performed a phase I clinical trial to assess the safety and feasibility of fecal microbiota transplantation (FMT) and re-induction of anti-PD-1 immunotherapy in patients with anti-PD-1-refractory metastatic melanoma. FMT donors were two metastatic melanoma patients who achieved a durable complete response. FMT recipient patients were metastatic melanoma patients who failed at least one anti-PD-1 line of treatment. Each recipient patient received FMT implants from only one of the two donors. FMT was conducted by both colonoscopy and oral ingestion of stool capsules, followed by anti-PD-1 re-treatment (Nivolumab, BMS). Recipient patients underwent pre- and post-treatment stool sampling, tissue biopsy of both gut and tumor, and total body imaging. Clinical responses were observed in three patients, including two partial responses and one complete response. Notably, treatment with FMT was associated with favorable changes in immune cell infiltrates and gene expression profiles in both the gut lamina propria and the tumor microenvironment.
Project description:Analysis of plasma from two human participants treated with 25 mg oral psilocybin capsules. Blood was collected at baseline, 1 hour, and 2.5 hours after treatment.
Project description:Gut microbiota dysbiosis characterizes systemic metabolic alteration, yet its causality is debated. To address this issue, we transplanted antibiotic-free conventional wild-type mice with either dysbiotic (“obese”) or eubiotic (“lean”) gut microbiota and fed them either a NC or a 72%HFD. We report that, on NC, obese gut microbiota transplantation reduces hepatic gluconeogenesis with decreased hepatic PEPCK activity, compared to non-transplanted mice. Of note, this phenotype is blunted in conventional NOD2KO mice. By contrast, lean microbiota transplantation did not affect hepatic gluconeogenesis. In addition, obese microbiota transplantation changed both gut microbiota and microbiome of recipient mice. Interestingly, hepatic gluconeogenesis, PEPCK and G6Pase activity were reduced even once mice transplanted with the obese gut microbiota were fed a 72%HFD, together with reduced fed glycaemia and adiposity compared to non-transplanted mice. Notably, changes in gut microbiota and microbiome induced by the transplantation were still detectable on 72%HFD. Finally, we report that obese gut microbiota transplantation may impact on hepatic metabolism and even prevent HFD-increased hepatic gluconeogenesis. Our findings may provide a new vision of gut microbiota dysbiosis, useful for a better understanding of the aetiology of metabolic diseases. all livers are from NC-fed mice only.
